SANJAY LAKHANI: Open Payments
NPI 1700962446 · HIGHLAND PARK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$650 in 36 payments from 8 companies in 2025. Trend: 2023 $386 · 2024 $451 · 2025 $650
Food & beverage: $650
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $210 |
| Novo Nordisk Inc | 9 | $148 |
| AstraZeneca Pharmaceuticals LP | 6 | $104 |
| GlaxoSmithKline, LLC. | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Gilead Sciences, Inc. | 1 | $23 |
| Cipher Pharmaceuticals US LLC | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
Products named: CAPLYTA, Saxenda, TRELEGY ELLIPTA, FARXIGA, REXULTI, Wegovy, Natroba, VOQUEZNA.
Industry payments across MI — which companies pay providers there.
